---

這是不是意味高端聯亞在取得美國FDA 認證EUA上將面臨新的變數。


網址https://reurl.cc/EnRexR


The U.S. Food and Drug Administration said on Tuesday it may decline to
review and process new emergency use authorization (EUA) requests for
COVID-19 vaccines for the rest of the pandemic, if a company has not already
begun discussions.

So far, vaccines from Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Johnson &
Johnson (JNJ.N) have been authorized for emergency use in the United States.
(https://bit.ly/3fOpP2S)

Novavax Inc (NVAX.O) has had discussions with regulators and said it does not
expect to seek regulatory authorization for its COVID-19 shot in the United
States, Britain and Europe until the third quarter of 2021. read more

Canadian drug developer Medicago said it was in discussions with the FDA for
an EUA for its plant-based COVID-19 vaccine candidate, which is enhanced by a
GlaxoSmithKline (GSK.L) treatment.


AstraZeneca (AZN.L) also has discussed plans for its COVID-19 vaccine with
U.S. officials. However, the Wall Street Journal earlier this month reported
that it was considering skipping U.S. emergency-use authorization and instead
pursue the more time-intensive application for a full-fledged license to sell
the shot. read more

AstraZeneca and Novavax did not immediately respond to requests for comment.

Our Standards: The Thomson Reuters Trust Principles.


這是真的嗎?

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 220.137.156.113 (臺灣)
※ 文章代碼(AID): #1WnPOjCy (Gossiping)
※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1623561773.A.33C.html